Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

A Novel Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

To evaluate the use of Life2000® Ventilator, a novel proportional open ventilation system in critical care use of acute onset of respiratory failure (ARF) and mild to moderate forms of acute respiratory distress syndrome (ARDS) in COVID-19 patients and its ability to provide effective ventilatory benefits and or delay patients from progressing to more aggressive forms of invasive mechanical ventilation (IMV).

Inclusion Criteria:

Patients who meet all of the following inclusion criteria and no exclusion criteria will be included in the study:

• A diagnosed or suspected COVID-19 patient requiring non-invasive ventilatory support and admitted to hospital
• PaO2/FiO2 ≤ 300 (corrected for altitude)
• RR ≤ 30/min during early use of oxygen
• Adults of 18 years and older
• Provision of written informed consent to participate in study by subject or legal representative.

Exclusion Criteria:

Patients who meet one or more of the following exclusion criteria will not be eligible for the study:

• Patients under the age of 18
• Patients who are not diagnosed or suspected of having an acute COVID-19 illness
• Patients who do not require non-invasive ventilatory interventions, PaO2/FiO2 > 300 (corrected for altitude) and tolerating supplemental oxygen with SpO2 saturations ≥ 92%.
• Patients who require immediate IMV upon admission or have a RR > 30/min on early oxygen intervention.
• Thoracoabdominal desynchrony and paradoxical breathing at admission
• Patients in immediate need of or on vasopressors upon ICU admission
• Patients or legal representatives who are unwilling or unable to provide written consent.